Myasthenia gravis (MG) is an autoimmune neurological disorder characterized by defective
transmission at the neuromuscular junction. The incidence of the disease is 4.1 to 30 cases …

Wnt, a secreted glycoprotein, has an approximate molecular weight of 40 kDa, and it is a
cytokine involved in various biological phenomena including ontogeny, morphogenesis …

Background There is an unmet need for treatment options for generalised myasthenia gravis
that are effective, targeted, well tolerated, and can be used in a broad population of patients …

Myasthenia gravis (MG) is an autoimmune disease characterized by muscle weakness and
fatiguability of skeletal muscles. It is an antibody-mediated disease, caused by …

Myasthenia gravis (MG) is an autoimmune disorder caused by autoantibodies that target the
neuromuscular junction, leading to muscle weakness and fatigability. Currently available …

Autoimmune diseases (AID) are increasingly prevalent conditions which comprise more
than 100 distinct clinical entities that are responsible for a great disease burden worldwide …

Myasthenia gravis (MG) is an autoimmune antibody-mediated disorder of neuromuscular
synaptic transmission. The clinical hallmark of MG consists of fluctuating fatigability and …

Muscle weakness and fatigue are the hallmarks of autoimmune neuromuscular junction
disorders. Although a plethora of immunosuppressive treatments exist, no cure is available …

Myasthenia gravis (MG) is the most common disorder of the neuromuscular junction. It is the
prototypic autoimmune disease most commonly caused by antibodies to the acetylcholine …

Autoimmune myasthenia gravis (MG) is characterized by muscle weakness caused by
antibodies directed against proteins of the neuromuscular junction. The main antigenic …